Generic Name: vorinostat
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.
Zolinza is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.
Zolinza is a capsule taken once daily with food.
Common side effects include diarrhea, fatigue, nausea and loss of appetite. Zolinza can cause depletion of red blood cells (anemia) and platelets (thrombocytopenia), which can lead to easy bleeding. Potential severe side effects include blood clots, gastrointestinal damage and high blood glucose. Zolinza may cause fetal harm if used during pregnancy.
Patient Assistance Program Info: http://www.merckhelps.com/ZOLINZA
Last Reviewed: November 29, 2018